Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
Sutapa SinhaRay GuoMiles D Del BussoWeiguo HanJustin BoysenLinda E WellikAsish K GhoshNeil E KayPublished in: British journal of cancer (2024)
Our findings that CLL cells likely are involved in driving SCC progression, at least in part, via activation of the AXL signaling axis, indicating that AXL inhibition may be beneficial for our CLL patients with SCC.
Keyphrases
- squamous cell carcinoma
- tyrosine kinase
- end stage renal disease
- chronic lymphocytic leukemia
- induced apoptosis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- cell cycle arrest
- oxidative stress
- cell death
- cell proliferation
- signaling pathway
- patient reported outcomes
- radiation therapy